US Ascites Market

ID: MRFR/MED/13959-HCR 100 Pages Nidhi Mandole Last Updated: September 15, 2026
US Ascites Market Research Report By Type (Transudative Ascites, Exudate Ascites), By Diagnosis (Ultrasound, CT Scan, Laparoscopy, Angiography), By Treatment (Surgeries) and By End User (Hospitals & Clinics, Ambulatory Surgical Center, Diagnostic Centers) - Growth & Industry Forecast 2025 To 2035
US Ascites Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.5%
2024 Market Size$ 336.4 Million
2025 Market Size$ 361.63 Million
2035 Market Size$ 745.25 Million
Key Players
Bristol-Myers Squibb
Roche
Novartis
Gilead Sciences
Merck & Co.
Amgen
Trends
  • Rising Incidence of Liver Diseases
  • Advancements in Diagnostic Technologies
  • Increased Awareness and Education
Opportunities
  • Growing Aging Population
  • Rising Healthcare Expenditure
  • Technological Innovations in Treatment
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
      1. 4.1.1 Transudative Ascites
      2. 4.1.2 Exudate Ascites
    2. 4.2 Industrial Automation & Equipment, BY Diagnosis (USD Million)
      1. 4.2.1 Ultrasound
      2. 4.2.2 CT scan
      3. 4.2.3 MRI
      4. 4.2.4 Blood test
      5. 4.2.5 Laparoscopy
      6. 4.2.6 Angiography
    3. 4.3 Industrial Automation & Equipment, BY Treatment (USD Million)
      1. 4.3.1 Medication
      2. 4.3.2 Paracentesis
      3. 4.3.3 Surgery
    4. 4.4 Industrial Automation & Equipment, BY Route of Administration (USD Million)
      1. 4.4.1 Oral
      2. 4.4.2 Parenteral
      3. 4.4.3 Others
    5. 4.5 Industrial Automation & Equipment, BY End-users (USD Million)
      1. 4.5.1 Hospitals
      2. 4.5.2 Specialty Clinics
      3. 4.5.3 Home Care
    6. 4.6 Industrial Automation & Equipment, BY Allotment Channel (USD Million)
      1. 4.6.1 Hospital Pharmacies
      2. 4.6.2 Retail Pharmacies
      3. 4.6.3 Online Pharmacies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Bristol-Myers Squibb (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Roche (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Novartis (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Gilead Sciences (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Amgen (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 AbbVie (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Johnson & Johnson (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
    4. 6.4 US MARKET ANALYSIS BY TREATMENT
    5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. 6.6 US MARKET ANALYSIS BY END-USERS
    7. 6.7 US MARKET ANALYSIS BY ALLOTMENT CHANNEL
    8. 6.8 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
    9. 6.9 RESEARCH PROCESS OF MRFR
    10. 6.10 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
    11. 6.11 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    12. 6.12 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
    13. 6.13 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
    14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
    15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 (% SHARE)
    17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
    18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 (% SHARE)
    19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 TO 2035 (USD Million)
    20. 6.20 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    21. 6.21 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
    22. 6.22 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USERS, 2024 (% SHARE)
    23. 6.23 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USERS, 2024 TO 2035 (USD Million)
    24. 6.24 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ALLOTMENT CHANNEL, 2024 (% SHARE)
    25. 6.25 INDUSTRIAL AUTOMATION & EQUIPMENT, BY ALLOTMENT CHANNEL, 2024 TO 2035 (USD Million)
    26. 6.26 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
      4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
      5. 7.2.5 BY END-USERS, 2025-2035 (USD Million)
      6. 7.2.6 BY ALLOTMENT CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Ascites Market Segmentation

US Ascites Market By Type (USD Million, 2025-2035)

  • Transudative Ascites
  • Exudate Ascites

US Ascites Market By Diagnosis (USD Million, 2025-2035)

  • Ultrasound
  • CT scan
  • MRI
  • Blood test
  • Laparoscopy
  • Angiography

US Ascites Market By Treatment (USD Million, 2025-2035)

  • Medication
  • Paracentesis
  • Surgery

US Ascites Market By Route of Administration (USD Million, 2025-2035)

  • Oral
  • Parenteral
  • Others

US Ascites Market By End-users (USD Million, 2025-2035)

  • Hospitals
  • Specialty Clinics
  • Home Care

US Ascites Market By Allotment Channel (USD Million, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.